Living evidence synthesis #21 (version 21.2): Appendices

Related Organizations

Table of Contents

• Effectiveness of the XBB.1.5 COVID-19 vaccines 1
• Living Evidence Synthesis 21 1
• Appendix 1a Summary of Included Studies new studies in blue 1
• 7 days since last dose 2
• 1-6 weeks since last dose 2
• 7-12 weeks since last dose 2
• 7 days since last dose 2
• 7 days since last dose 2
• No prior infection 2
• 7 days since last dose 2
• Infection 1 year ago 3
• 7 days since last dose 3
• Infection 1 year ago 3
• 7 days since last dose 3
• 7 days since receiving the XBB.1.5 variant adapted vaccine 7-59 days since receiving the XBB.1.5 variant adapted vaccine 3
• 59-119 days since receiving the XBB.1.5 variant adapted vaccine 3
• Received their previous non XBB vaccine more than 12 weeks ago 4
• Received their previous non XBB vaccine more than 12 weeks ago 4
• Had a previous COVID-19 infection 4
• Excluding individuals who tested positive for influenza from the COVID-19 control group 4
• Had a previous COVID-19 infection and excluding individuals who tested positive for influenza from the COVID- 19 control group 5
• Compared to individuals who received the BA.45-adapted bivalent vaccine but no XBB.1.5-adapted vaccine. 5
• Compared to individuals who received 3 doses of wild-type vaccine but no variant- adapted vaccines of any kind. 5
• Compared to individuals who received 2 doses of wild-type vaccine but no variant- adapted vaccines of any kind. 6
• Compared to individuals who were unvaccinated. 6
• Compared to individuals who received the BA.45-adapted bivalent vaccine but no XBB.1.5-adapted vaccine. 6
• Compared to individuals who received 3 doses of wild-type vaccine but no variant- adapted vaccines of any kind. 7
• Compared to individuals who received 2 doses of wild-type vaccine but no variant- adapted vaccines of any kind. 7
• Compared to individuals who were unvaccinated. 7
• Compared to individuals who received the BA.45-adapted bivalent vaccine but no 7
• XBB.1.5-adapted vaccine 8
• Compared to individuals who received 3 doses of wild-type vaccine but no variant- adapted vaccines of any kind. 8
• Compared to individuals who received 2 doses of wild-type vaccine but no variant- adapted vaccines of any kind. 8
• Compared to those who were unvaccinated. 8
• References 10
• Appendix 1b Summary of studies excluded for critical risk of bias Study ID First author Title Reason for critical bias decision 11
• 02V-1 11
• SES socio-economic status 11
• Appendix 2 VE against other COVID-19-related outcomes e.g. outpatient visits of the XBB.1.5 adapted COVID-19 vaccine compared to those who have not received the XBB.1.5 adapted COVID-19 vaccine 12
• Appendix 3 Search strategy Medline and Embase Row Syntax 14
• NIHiCite except PubMed Syntax Filters 14
• Appendix 4 Definitions and glossary Full vaccine series 15
• Fully vaccinated Additional dose 15
• Confirmed infection Hospitalisation due to COVID-19 ICU admission due to COVID-19 Death due to COVID-19 Post-COVID-19 conditions MIS-C 15
• Variants of concern VOC Vaccine effectiveness VE Relative vaccine effectiveness AZ CIs ED HCW ICU LTC LTCF MOD Obs Omicron OR PF 16
• RCT RoB UC UK USA VOI WHO 17
• Appendix 5 Critical appraisal process Low Moderate Serious Critical or No Information 18
• Low Risk of Bias indicates High Quality and Critical Risk of Bias indicates Very Low insufficient Quality 18
• Appendix 6 Data-extraction template Study details 19
• Outcomes 20
• Appendix 7a Flow chart of studies included in the current update 21
• Appendix 7b. Summary of excluded studies during full text screening new studies are in blue 22
• Author year of publication Title Reason for exclusion 22
• Appendix 7b. Summary of excluded studies during hand search new studies are in blue 23
• Author year of publication Title Reason for exclusion 23